KPTIKaryopharm Therapeutics Inc.同业对比
Karyopharm Therapeutics Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KPTI本股 | $2M#8 | — | — | 0.0x#1 | 0.6%#2 | -156.5%#14 | -62.1%#1 | — | — | — | -98.2%#6 | — |
| KALA | $3M#1 | 0.0x#2 | 0.4x#6 | — | — | 29.9%#6 | — | -298.3%#10 | -69.9%#1 | — | — | — |
| DRMA | $3M#2 | — | 0.9x#10 | — | — | 38.5%#5 | — | -216.7%#8 | — | — | — | — |
| SXTP | $3M#3 | — | 1.2x#11 | 3.2x#6 | 65.5%#1 | 7.3%#8 | -771.6%#4 | -281.7%#9 | -163.8%#3 | 6#1 | — | — |
| PTPI | $3M#4 | 0.1x#6 | 3.8x#13 | 0.5x#2 | -12.2%#4 | 113.4%#1 | -90.8%#2 | 273.0%#1 | — | — | — | — |
| BFRGW | $3M#5 | — | 0.4x#5 | 22.2x#7 | — | 7.1%#9 | -5652.4%#7 | -93.0%#3 | -5287.3%#5 | — | — | — |
| APVO | $2M#6 | 0.0x#3 | 0.4x#7 | 0.8x#3 | -74.7%#7 | -7.6%#12 | -845.0%#5 | -429.8%#11 | — | — | -95.1%#4 | — |
| ZVSA | $2M#7 | — | — | — | — | -165.1%#15 | — | — | — | — | — | — |
| HCWB | $2M#9 | 0.0x#5 | 0.3x#4 | 40.0x#9 | -97.9%#8 | 73.5%#4 | -24270.7%#9 | -107.2%#5 | -99.4%#2 | 3#2 | — | — |
| ONCO | $2M#10 | 0.0x#1 | 0.2x#2 | 2.6x#5 | -67.7%#5 | 76.1%#2 | -2190.0%#6 | -104.2%#4 | — | — | -99.7%#7 | — |
| BIVIW | $2M#11 | — | 0.2x#3 | — | — | -25.8%#13 | — | -214.9%#7 | -1671.2%#4 | — | -19.7%#1 | — |
| SILO | $2M#12 | 0.4x#8 | 0.4x#8 | 27.4x#8 | 0.0%#3 | 3.8%#11 | -5937.0%#8 | -86.5%#2 | — | — | — | — |
| GNPX | $2M#13 | 0.0x#4 | 0.1x#1 | — | — | 24.1%#7 | — | -109.7%#6 | — | — | -98.2%#5 | — |
| JUNS | $2M#14 | — | — | 82.7x#11 | — | -254.4%#16 | -40873.2%#11 | — | — | — | — | — |
| OGEN | $2M#15 | 0.4x#7 | 0.5x#9 | 44.6x#10 | -71.4%#6 | 6.9%#10 | -24865.2%#10 | -26814.1%#13 | — | — | -69.5%#3 | — |
| ATXI | $1M#16 | — | 2.4x#12 | 1.0x#4 | — | 75.0%#3 | -219.6%#3 | -511.2%#12 | — | — | -50.4%#2 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-02。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议